| abstract |
The disclosed methods generally address steps to prevent, treat, suppress, control or otherwise mitigate side effects of T cell therapy, where T cell therapy accelerates immune reconstitution and implants. Designed to induce anti-malignant effects and / or target tumor cells. In some embodiments, the present disclosure provides an expression vector comprising a first expression control sequence operably linked to a first nucleic acid sequence, the first nucleic acid sequence being hypoxanthine-guanine phosphoribosyltransferase. It encodes a knockdown shRNA. [Selection diagram] Fig. 1 |